You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 21, 2024

Investigational Drug Information for Prexasertib

✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Prexasertib?

Prexasertib is an investigational drug.

There have been 18 clinical trials for Prexasertib. The most recent clinical trial was a Phase 2 trial, which was initiated on April 10th 2018.

The most common disease conditions in clinical trials are Neoplasms, Central Nervous System Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and National Cancer Institute (NCI).

There are six US patents protecting this investigational drug and one hundred and seventy-one international patents.

Recent Clinical Trials for Prexasertib
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial CarcinomaGOG FoundationPhase 1/Phase 2
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial CarcinomaAcrivon TherapeuticsPhase 1/Phase 2
A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and RhabdomyosarcomaMemorial Sloan Kettering Cancer CenterPhase 1/Phase 2

See all Prexasertib clinical trials

Clinical Trial Summary for Prexasertib

Top disease conditions for Prexasertib
Top clinical trial sponsors for Prexasertib

See all Prexasertib clinical trials

US Patents for Prexasertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Prexasertib ⤷  Sign Up Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign Up
Prexasertib ⤷  Sign Up 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitfile (S)-lactate monohydrate Eli Lilly and Company (Indianapolis, IN) ⤷  Sign Up
Prexasertib ⤷  Sign Up Targeted therapeutics MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA) ⤷  Sign Up
Prexasertib ⤷  Sign Up PD-1/PD-L1 inhibitors Gilead Sciences, Inc. (Foster City, CA) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Prexasertib

Drugname Country Document Number Estimated Expiration Related US Patent
Prexasertib Australia AU2017261372 2036-05-05 ⤷  Sign Up
Prexasertib Canada CA3023278 2036-05-05 ⤷  Sign Up
Prexasertib China CN107847398 2036-05-05 ⤷  Sign Up
Prexasertib European Patent Office EP3452003 2036-05-05 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.